Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sequential CART cells with different B-cell targets in relapsed/refractory aggressive B-cell lymphoma
ChiCTR2100055062Phase 2Recruiting
- Sponsor
- Beijing Boren Hospital
- Start
- Dec 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CAR-T cells (CD19/CD22/CD20-targeted) in aggressive B-cell lymphoma, sponsored by Beijing Boren Hospital. Primary endpoint: Efficacy evaluation index. Started Dec 2021; status: recruiting.
02
Drugs
CAR-T cells (CD19/CD22/CD20-targeted)
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on ChiCTR2100055062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100055062.